If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

PDMR Dealing

24 Apr 2018 17:04

RNS Number : 9918L
Omega Diagnostics Group PLC
24 April 2018
 

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

 

PDMR Dealing

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it was notified on 24 April 2018 that Edward Valente, Group R&D Director of the Company has purchased 124,044 ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") at a price of 14.5 pence per Ordinary Share.

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1)

Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')

a)

Name

Edward Valente

2.

Reason for notification

b)

Position / status

Group R&D Director

c)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

Name

Omega Diagnostics Group plc

c)

LEI

2138007U9P4BTZTYIR92

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 Identification code

 

Purchase of Ordinary Shares

 GB00B1VCP282

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Volume(s)

Price(s) £

124,044

0.145

 

d)

Aggregated information

Aggregated volume Price

Aggregate Volume(s)

Volume weighted average Price) £

124,044

0.145

 

e)

Date of the transaction

24/04/18

f)

Place of the transaction

LSE

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Colin King, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

Jag Grewal, Group Sales and Marketing Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

 

Camille Gochez (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKQDKABKDBQB
Date   Source Headline
16th Apr 200710:36 amRNSEuropean patent grant
4th Apr 20077:02 amRNSAppointment of Distributor
30th Mar 20076:20 pmRNSInterim Results
15th Dec 20062:28 pmRNSTotal Voting Rights
6th Nov 20067:00 amRNSEuropean patent grant
4th Oct 20069:37 amRNSIssue of Equity
27th Sep 20067:00 amRNSInterim Results
20th Sep 20065:15 pmRNSChange of Name
19th Sep 20067:02 amRNSCommencement of dealings
18th Sep 20062:58 pmRNSResult of EGM
5th Sep 200612:13 pmRNSSch1-Quintessentially English
24th Aug 200611:51 amRNSRestoration of Trading-Amend
24th Aug 200610:30 amRNSRestoration of Trading
24th Aug 200610:30 amRNSRestoration-Quintessentially
24th Aug 20067:00 amRNSAcquisition and Placing
8th May 200612:34 pmRNSResult of AGM
3rd Apr 20067:02 amRNSTemporary Suspension
3rd Apr 20067:01 amRNSSuspension - Quintessentially
23rd Mar 20064:13 pmRNSFinal Results
28th Sep 20057:02 amRNSInterim Results
12th Aug 200512:17 pmRNSResult of AGM
28th Jun 200511:40 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.